Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
Tweet Send to a Friend
Piper Jaffray & Co. maintains an Overweight rating on ISIS Pharmaceuticals (Nasdaq: ISIS), lowers price target from $25 to $15 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
